Search
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.
Teicoplanin
go.drugbank.com/drugs/DB06149ApprovedInvestigationalWithdrawnTeicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). … All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
Pizotifen
go.drugbank.com/drugs/DB06153ApprovedSandomigran is available in a number of countries but is not approved by the FDA nor EMA. … [A32532] It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years.
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexZosuquidar
go.drugbank.com/drugs/DB06191InvestigationalZosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt will compare pixantrone efficacy to that of gemcitabine. [2] … Pixantrone does not bind iron and promotes the formation of reactive oxygen species to a lesser degree than other anthracyclines.
Icatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigationalIcatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B<sub>2</sub> receptors with a similar affinity to bradykinin. … It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B<sub>2</sub> receptors antagonists, thus representing a new class of medication.
Rufinamide
go.drugbank.com/drugs/DB06201ApprovedRufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.
Sugammadex
go.drugbank.com/drugs/DB06206ApprovedInvestigationalSugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.
Categories: Compounds used in a research, industrial, or household setting